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(57) ABSTRACT 
System and method for performing one or more relevant 
measurements at a target site in an animal body, using a 
probe. One or more of a group of selected internal measure- 
ments is performed at the target site, is optionally combined 
with one or more selected external measurements, and is 
optionally combined with one or more selected heuristic 
information items, in order to reduce to a relatively small 
number the probable medical conditions associated with the 
target site. One or more of the internal measurements is 
optionally used to navigate the probe to the target site. 
Neural net information processing is performed to provide a 
reduced set of probable medical conditions associated with 
the target site. 
22 Claims, 6 Drawing Sheets 
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BODY SENSING SYSTEM 
This application is a Division of an application, U.S. Ser. 
No. 091652,302, filed 28 Aug. 2000, now abdn. 
ORIGIN OF THE INVENTION 
The invention disclosed herein was made by employees of 
the United States Government and may be manufactured and 
used by or for the Government €or governmental purposes 
without payment of any royalties for such manufacture and 
use. 
FIELD OF THE INVENTION 
This invention relates to navigation to, and imaging, 
sensing, diagnosing, and providing a prognosis for a medical 
condition of, a target site within a human or animal body. 
BACKGROUND OF THE INVENTION 
Use of a conventional surgical procedure to provide a 
diagnosis andor prognosis on a patient is necessarily inva- 
sive. Where a surgical probe is used to reduce the invasive- 
ness, the procedure is often performed blindly or with 
indirect image guidance, with little accurate information on 
the location of the probe and/or whether the probe has 
located, navigated to or reached the target site. One result of 
a conventional approach is an increased number of false 
positive test results and false negative test results that 
directly affect the diagnostic results and the results of 
subsequent surgery at the target site. For example, about 37 
percent of patients undergoing epidural anesthesia require 
three or more attempts at epidural placement. In another 
direction, about 20 percent of instances of prostate cancer 
are missed (false negative test result) by performance of a 
blind biopsy. 
What is needed is a system and associated method that 
allows navigation to a target site and uses results from 
several different tests to identify a malignancy, a disease, a 
benign condition, a normal condition or any other medical 
condition (collectively referred to as “medical conditions” 
herein) at the target site from a reduced group of such 
conditions that may be present, consistent with the data 
obtained from various measurements and other information. 
Preferably, the system should work with quantitative mea- 
surements, with qualitative measurements and with other 
relevant information on the subject and the subject’s family. 
Preferably, the system should allow inclusion or exclusion of 
one or more selected measurements and information items 
without reconfiguration of the analysis of the data presented 
and should allow assignment of selected weights to different 
data items, corresponding to the importance of a data item 
in identifying presence of a particular medical condition. 
SUMMARY OF THE INVENTION 
These needs are met by the invention, which provides an 
active system for measuring and determining the location, 
geometric parameters and medical condition(s) of a target 
site (organelle, cell, tissue, organ, etc.) within the body of an 
animal or a human being (collectively referred to herein as 
“animal”). The system relies upon measurements and other 
information from one or more of at least three types of 
sources: external measurements, from sources such as 
lymph node sampling, manual palpitation of the target site, 
mammograms, ultrasound scans, NMRI scans, CAT scans, 
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estimation of target site size, surface roughness and/or 
calcification at the site and other similar functionalities; 
internal sensor measurements, including mechanical stiff- 
ness, thermal responsiveness, optical reflectance and imag- 
ery, target margin behavior, blood flow estimation, intersti- 
tial fluid pressure, vascular size, density and architecture, pH 
and electrical characteristics; and heuristic information 
involving prior medical history of the test subject and the 
subject’s family. 
Most or all of the measurements and information items 
are used to estimate the present location, present size and 
other geometric parameters, present medical condition and/ 
or prognosis of the target site, by excluding or ruling out 
certain location and/or geometric parameters andor other 
medical conditions. No one test determines the results. Most 
or all of the measurements are used in combination to 
estimate the present medical condition of the target site. 
Each internal measurement, external measurement and 
heuristic information item that lies in a selected range 
indicates possible presence of a group of medical conditions 
that is wholly, or largely, consistent with these data. In one 
approach, the set intersection of these different groups may 
be formed to provide a reduced group of medical conditions 
that is wholly, or largely, consistent with these measure- 
ments and information items. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic view of use of the system to sense 
a target site in a human’s body according to the invention. 
FIG. 2 illustrates, in block diagram format, some of the 
four types of measurements used in practicing the invention. 
FIG. 3 graphically illustrates formation of a set intersec- 
tion of groups of possible medical conditions according to 
the invention. 
FIGS. 4 A 4 D  graphically illustrate data and a result of 
analysis of these data according to the invention. 
FIG. 5 is a schematic view of a probe constructed accord- 
ing to the invention. 
FIG. 6 is a flow chart of a procedure to practice the 
invention. 
FIG. 7 is a schematic view of one approach to neural 
network modeling and processing of information provided 
by the invention. 
FIGS. 8A and 8B are one-dimensional illustrations of a 
comparison of reference data points and observed data 
points according to the invention. 
DESCRIPTION OF BEST MODES OF THE 
INVENTION 
FIG. 1 illustrates use of the invention-to interrogate a 
target site 11 (organelle, cell, tissue, organ, etc.) in an animal 
body 13 according to one embodiment of the invention. A 
sensor or probe is inserted into the body 13 adjacent to the 
target site 11 and is activated to provide one or more internal 
measurements, which set forth in more detail in FIG. 2. A 
region of the body 13 adjacent to the target site is immobi- 
lized (to the extent this is possible) by a stereotactic or other 
body-holding device 15, and a sensor assembly or probe 17 
is positioned adjacent to or within the target site, outside or 
inside the body. Internal measurements data are sensed or 
measured by the probe 17 and are received and stored by an 
internal data base 21. An internal data base 22, an external 
data base 23 and a heuristic database 25 hold internal 
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measurements data external measurements data and heuris- 
tic information, respectively, also set forth in greater detail 
in FIG. 2. 
FIG. 2 sets forth three kinds of data that are used to help 
determine one or more medical conditions of the target site 
13: internal measurement sets, external measurements and 
heuristic information. Internal measurements include: (1) 
elasticity parameters of the target site and surroundings; (2) 
thermal parameters of the target site and surroundings; (3) 
optical reflectance of selected portions of, or all of, the target 
site surface and/or interior; (4) target margin characteristics 
for the target site; (5) estimates of blood flow within and/or 
adjacent to the target site; (6) vascular size, density andpr 
architecture within and/or adjacent to the target site; (7) 
interstitial fluid pressure within and/or adjacent to the target 
site; (8) oxygen tension p02 in a selected region within 
and/or adjacent to the target site; (9) pH of a selected region 
within and/or adjacent to the target site; (IO) electrical 
parameters of a selected region within and/or adjacent to the 
target site; and (11) other relevant parameters. 
Elasticity parameters include Young’s modulus (resis- 
tance to strain imposed in a first direction when the body is 
unconstrained in any transverse direction), bulk modulus 
(resistance to change of three-dimensional volume), Pois- 
son’s ratio (change in dimension in a first direction in 
response to an imposed change in dimension in a second 
direction), and other similar parameters. One or more of the 
elastic parameters can be determined by observing a target 
site response to an abrupt step function force, to a slowly 
applied mechanical force and/or to a time varying force 
(such as a sinusoidal force). For example, presence of a 
tumor at a target site may increase the Young’s modulus by 
400-900 percent, relative to the Young’s modulus of a 
normal or healthy target site. No single parameter obtained 
from internal measurements is sufficiently specific that mea- 
surement and comparison of these parameter values with 
corresponding values for a “normal” target site will deter- 
mine, by themselves, the nature of the abnormality present. 
Thermal parameters include local temperature, thermal con- 
ductivity and specific heat capacity of a selected region 
adjacent to or within the target site. Specific heat capacity of 
a normal organ or tissue, for example, has an estimated 
range of about cp=0.9-1 cal/gm/’ C., whereas an organ or 
tissue that includes a tumor may have a higher range for cp 
(reflecting the more “solid” nature of a tumor) M may have 
a lower range for cp (reflecting the interrupted and irregular 
nature of blood flow, and thus temperature regulation, within 
a tumor). The temperature of a normal organ or tissue within 
a human may have a range T= 37-38’ C., whereas the 
temperature of an organ or tissue with certain diseases 
present may have a range several degrees Celsius higher. 
Optical reflectance of a selected portion of, or all of, a 
target site is best evaluated by dividing a selected region of 
wavelengths h, for example, 200 nm 3.11200 nm, into 
wavelength bins of selected length A i ,  where A?L may be 10 
nm-100 nm, depending upon the medical condition being 
assessed. Optical reflectance OR(h;meas), measured for the 
target site, is compared with “normal” optical reflectance 
OR(h;normal) for each of a selected sequence of wavelength 
ranges to estimate whether the target site is abnormal, and if 
so, what is the group of medical conditions that presently 
atfect the target site. 
J. Mourant et al, in “Spectroscopic Diagnosis of Bladder 
Cancer With Elastic Light Scattering, Lasers in Surgery and 
Medicine, vol. 17 (1995) pp. 350-357, have examined ten 
patients with suspected bladder cancer, using one or more 
optical fibers to illuminate a region and another optical fiber 
to collect the backscattered light in a wavelength range 250 
nm Sh1900 ML These optical biopsy results were com- 
pared with actual biopsies performed at the same sites. After 
subtracting a dark background that is common to all mea- 
5 surements at each of a sequence of wavelengths, these 
workers found that for 20 malignant regions, the normalized 
optical reflectance spectrum had a strong negative slope in 
the wavelength region 330 nm 1h1370, while 29 of 30 
nonmalignant regions had a normalized optical reflectance 
io spectrum with a modest positive slope for the same wave- 
length region; the specificity for this test, based on the ten 
patients examined, is 97 percent. 
Use of optical reflectance to serve as a guide in navigating 
a probe within brain tissue, and distinguishing white matter 
15 from gray matter therein, is reported by H. Liu et al in 
“Investigation of Optical Reflectance from Human Brain in 
vivo for Guiding Brain Surgery” [citation]. White matter 
reflectance is 3-5 times as large as gray matter reflectance in 
a wavelength region 600 nm St.5800 nm, and this differ- 
20 ence appears to extend to higher and lower wavelengths as 
well. A transition region near the gray-white matter bound- 
ary witin a brain has optical reflectances that are interme- 
diate between the gray matter and white matter values. 
The margins of certain tumors may have certain charac- 
25 teristics that differ from the corresponding characteristics for 
the core or interior of the tumor. For example, the increased 
interstitial fluid pressure in the core of a tumor drops sharply 
to that of a normal region near an edge of a tumor, as 
reported by P. Vaupel, in “Vascularization, blood flow, 
30 oxygenation, tissue pH, and bioenergetic status of human 
breast cancer”, Oxygen Transport to Essue, Plenum Press, 
New York, vol. 18 (1997), pp. 143-154, and discussed in 
greater detail in the following. Comparison of these char- 
acteristics for the ma.rgin(s) and for the core, using selected 
35 scanning or imaging techniques, may help distinguish 
between the presence and absence of certain kinds of 
tumors. The size of a margin or transition region may also 
indicate presence of a non-normal target site. For example, 
a margin size for a well developed tumor is typically about 
An estimate can be made of blood flow velocity adjacent 
to or within the target site using a sensor that estimates blood 
flow using a Doppler velocity sensor or similar indirect 
estimating procedures. For a normal breast, a breast with a 
45 benign tumor and a breast with a malignant tumor, measured 
mean blood flow values are 311f157 flux units, 482fl09 
flux units and 711k280 flux units, respectively. Thus, larger 
than normal blood flow velocity appears to indicate presence 
of a benign or malignant tumor. 
Where measured vascular density for a target site is 
higher, by a multiplicative factor of 2-10 or higher, than a 
normal range of vascular density (e.g., 2-3 per mm2) for that 
site, this condition often indicates the prezence of a malig- 
nant tumor. Comparison of measured vascular size with 
55 vascular size range for a normal target site (e.g., 0.2 mm) can 
indicate presence of a class of non-normal medical condi- 
tions (benign or malignant), especially if the measured size 
is at least 200 percent higher than the normal range of sizes. 
P. Vaupel, op cit, notes that growth of an avascular, 
60 three-dimensional aggregate of tumor cells is self-limiting. 
The establishment of progressive expansion of malignant 
tumors is possible only if supply and drainage are initiated 
through blood flow through exchange vessels in a tumor bed, 
using pre-existing normal host blood vessels and using 
65 newly-formed tumor vessels arising from neovasculariza- 
tion. Angiogenesis, the formation of new capillaries from an 
existing vascular network, appears to be essential for tumor 
40 2.7 mm. 
50 
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growth and metastasis, and some angiogenesis parameters Vaupel, op cit, reports that the intracellular pH is neutral 
(p02, vascular count, vessel morphology, etc.) can also be to mildly alkaline for tumorous cells that are not deprived of 
used for prognosis. Greater vascular density may be asso- oxygen or energy, while the extracellular pH is acidic. This 
ciated with longer patient survival, although some other cross-membrane gradient for a tumorous cell is opposite in 
studies reach an opposite conclusion. A growing tumor is 5 sign to the cross-membrane gradient for a normal cell, where 
unable to form its own lymphatic system and must rely on PH(mtraCellUlar) is lower than PH(exmlldar).  
other sources for blood, nutrients, oxygen, etc. Bulk flow of A. J- ~Urowiec et al, in 1.E.E.E. Trans. 0x1 €bmedical 
free fluid in interstitial spaces appears to be much higher in Engineering, VOl. 35 (1988) PP. 257-2629 report 0x1 mea- 
a tumorous region than in a normal region: 15 percent of SuT-XlCXltS Of dielectric PXaIIleterS at frqUenCieS UP to 100 
n o d  convective plasma flow for breast cancer regions 10 MHz. These workers find that electrical conductivity in 
versus 0.5-1 percent of normal convective plasma flow for hmOrOUS breast tissue is 1Oo-200 Percent higher than 
a normal region. These increased interstitial fluid pressures electrical conductivity h normal breast tissue: 2-3 mS/cm 
drop sharply near the edge of a tumor. versus about 1 mS/cm. Other tissues are believed to be 
Interstitial fluid m) is a of a balance 
site. only an invasive breast tumor has a consistently higher 
IFF' value (15-32 mm Hg) than does a normal or healthy 
needle tip is located within the tumor region. The results 
also relevant here. 
Of Oxygen tension PO2 (Or '") for a 
selected region adjacent to or within the target site with 
similarly affected by changes in structure and composition, 
differences in electrical conductivity and other dielectric 
parameters is expected for Other tissues* 
assist the probe in navigating to the target site, preferably in 
to be known, and imaging of the organs and major tissue 
groups to move the probe to a location adjacent to the target 
site. At this location, the probe can perform certain internal 
measurements outside the target site, before the probe is 
of fluid a target site and fluid exiting from the target 15 due to cell proliferation and tumor growth, and S i d a r  
breast ( 4 . 4  to +4 - Hg), where an measurement The and probe l7 can be to 
reported in the preceding paragraph by Vaupel, op tit, are 2o real time. One here general shapes, assumed 
corresponding values for a normal 
indication Of whether not a Particular Of medical 
conditions is present. vauPel, Kallinowski and Okunieff? in 
site can Provide an 25 moved within the probe site for additional measurements. 
Data from external measurements, not relying upon mea- 
surements taken with the Sensor assembly and probe 17, may 
Oxygen and Nutrient and also help limit the class of medical conditions, if any, present 
Microenvironment of Human Tumors; AReview", [citation] at the target site. one example is data extracted from 
report on a study of change of p02 in cervical mucosa with 3o mammogram imaging performed on an adult female. This 
disease (e.g., cancer of the breast); (2) be consistent with, but 
measured PO2 value appears to move to lower and lower 35 indicative of, the presence of a particular disease. Another 
values as cancer progresses, as example is a protein specific antigen (PSA) test, performed 
progress of cervical cancer. In a normal, non-cancerous image may: (1) indicate the likely presence of a 
the the PO2 median value is 36 Hg. For stages 
and Of cervical cancer, the PO2 median value to - Hg, respectively. The not unambiguously indicate the presence of, a particular disease; or (3) may be inconsistent with, or be contra- 2o mm Hg, to l3 Hg and to 
to a normal Or 
healthy range for the cervix. A non-metastasising breast on an adult male, to detect the (increasing) likelihood of 
tumor (p02=20 mm Hg) has a larger mean ~ 0 2  value than presence of prostate cancer. 
does a metastasising breast tumor (p02=7.5 mm Hg). Based are the NMRI 
on other measurements reported, a tumor growing in asso- 4o scans, scans, ultrasound scans and m ~ o g r a m s ,  
more Oxygen than a normal Organ, and this may be mani- compared with data from measurements on normal target 
fested by a much smaller p02 value where a tumor is sites. 
Another class of external measurements are lymph node present. 
Results reported by VaUPel, OP city on Oxygen consump- 45 samples, which may indicate presence of a normal medical 
tion in a breast C a ~ ~ e r  tumor (3-10 Plkdmin) Versus condition or of a precursor or a vestige of a non-normal 
Oxygen ConsUmPtion in anormal region (3-6 !&@fin) are medical condition, such as HIV, that is not yet present, or is 
consistent with these results. Hypoxia is present in no longer present, at other sites within a body, 
~morous  regions. VaUPel found Po2 values Of O-2.5 - Hg Another class of external measurements involve simple 
forbreasttUmors and Po2 Values of at least 12.5 mm Hg for 50 manual palpitation of a region of a body and comparison of 
normal regions. A bimodal $2 distribution is often mani- the response with an expected response from a normal, 
fested, indicating presence of normal and hypoxic regions undiseased body. 
side by side. The size andor shape of a target site cm be estimated, 
The pH of a selected region adjacent to or within a target using scanning or imaging (NMRI or ultrasound), or using 
site can be measured and compared with a normal range of 55 a sequence of two or more measurements, taken at different 
pH for the target site, as an indicator of the possible presence locations relative to the target site, and some analytical 
of one or more of a class of medical conditions. A normal geometry computations to estimate the parameters of an 
target site will have a steady state pH of 7-7.4, reflecting the ellipse that approximately coincides with the target site, as 
corresponding values of blood pH. Extracellular pH has a discussed in the following. 
mean value of 7.35 for a normal target site and 7.0 for a 60 The roughness (spiculation) of a target site surface can be 
tumorous target site. Intracellular pH has a mean value of estimated using an NMRI scan or ultrasound scan. Spicu- 
7.04 for a normal target site and 7.2 for a tumorous target lation associated with a boundary of a tumorous target site 
site. For a tumorous cell, pH(intracellu1ar) is significantly may differ significantly from spiculation of an adjacent 
greater than pH(extracellu1ar). However, mislocation of the normal site. This difference should be evident from the 
site of measurement of pH (inside versus outside a cell) may 65 results of an NMRI scan or ultrasound scan, if the region 
lead to a wrong conclusion concerning the condition of the interrogated can be made smaller than the present size of a 
cell or target site. tumor. 
Another class of external 
ciation with an Organ appears to require at least 50 percent which provide data on or adjacent to a target site that can he 
US 6,976,013 B1 
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A measurement or other estimate of the amount of calci- groups numbered 1, 3 and 7 of the internal measurement 
fication associated with a target site can be estimated, using data and group number 2 of the external measurement data, 
optical imaging, NMRI scanning, ultrasound scanning or as an example. 
(preferably) a mammogram, and can be compared with the Internal measurement data, external measurement data 
amount and pattern of calcification associated with a normal 5 and heuristic information are preferably analyzed using a 
or benign target site to determine whether a class of medical neural network that is configured as discussed in the fol- 
Size, surface roughness and calcification associated with FIGS. 4A, 4B and 4 c  graphically illustrate Certain Fan-  
a target site are (somewhat arbitrarily) treated as external titative external measurement data that might be obtained for 
measurements because these parameters are often obtained 10 a target Site at which a tumor may be Present, indicating 
using NMRI andor ultrasound scanning to provide the data. target Site Size WG. 4A), spiculation (FIG. 4B) and shape 
However, one or more of these information items could also (FIG. 4c). FIG. 4D indicates a possible result of analysis of 
be treated as an internal measurement. the results obtained from the data shown in FIGS. 4A, 4B 
and 4C. In this instance, the confidence level that the target 
his,ry of the subject and of the subject,s family, may be 15 site includes a malignant tumor is about 25 percent, which 
may be large enough to performance Of more 
invasive 
FIG. 5 is a schematic view of a sensor assembly and probe 
17 including mechanisms to perform measurements associ- 
20 ated with each of the ten types of internal measurements 
discussed in the preceding. A first probe mechanism 17-1 
measures one or more elastic parameters associated with the 
target site, preferably including at least one of Young’s 
modulus and bulk modulus. A second probe mechanism 
conditions is likely to be present. lowing. 
Heuristic information, including but not &ted to 
used to provide an indicator of consistency or inconsistency 
of an extant prognosis determined from internal andor 
external measurements, For example, the subject,s family 
may have an extensive medical history of cancer involving 
a particular group of organs (e.g., breast, prostate and colon), 
which should be taken into in any diagnosis or 
prognosis at a target site. 
The external measurements and the heuristic information 
and corrective surgery. 
Provide data that are often not and 25 17-2 measures one or more thermal parameters, &-awn from 
a group consisting of local temperature and specific heat with conesPonding data for a normal target site. 
The external measurements data and/or heuristic informa- capacity associated with the target site. A third probe mecha- 
that does not ’IJon Of values but selected region of the target site for one or more selected 
that not that a particular medical condition is, or is not, sures one or more characteristics of the margin of a target 
present. For example, comparison of a calcification pattern site. A fifth probe mechanism 17-5 measures mount of 
for an observed target site with a calcification pattern for a blood flow adjacent to or within the target site. A sixth probe 
are Preferably analyzed using a logic interface nism 17-3 measures optic- reflectance OR(h;meas) of a 
that can retmn a (fuzzy) determination that it is more likely 30 wavelength ranges. A fourth probe mechanism 17-4 mea- 
conesponding normal target site may ’e performed mechanism 174  measures vascular size and/or vascular 
and subjectiveiy by a health may be 35 density associated with the target site. A seventh probe 
performed by a algorithm, logic mechanism 17-7 measures interstitial fluid pressure associ- 
and the nature Of the pattern differences rather than ated with the target site. An eighth probe mechanism 17-8 
Professional 
a 
hard-edged Of One Or more numerical param- measures oxygen tension p02 associated with the target site. 
and S. Isaka in “Fuzzy Logic”, Scientific American, July with a selected portion of the target site. A tenth probe 
mechanism 17-10 measures one or more electrical param- 
of the Preceding N1=10 groups of internal eters associated with a selected portion of the target site. One 
measurements, from the N2=7 groups of external mmure- or more of these probe mechanisms can be included in the 
merits and/or from the N3=2 groups of heuristic information probe; and one or more of these probe mechanisms can be 
are Preferably analyzed using a direct interface With ana- 45 included in each of two probes that cooperate to sense and 
1YtiCal Software that is Part of the system. some of these measure various internal data for comparison. Optionally, 
mmerical data may be directly compared with ConeSPond- the probe 17 may also be configured to measure one or more 
ing m ~ ~ ~ r i c a l  ranges to determine Whether a Particular parameters associated with size, shape, surface roughness 
medical condition is likely to be present at the target site. and/or calcification pattern associated with a target site. 
Each group of internal nwmrement data, each group of 50 FIG. 6 is a flow chart of a procedure for practicing the 
external nwisurement data and each WUP of heuristic invention. In step 61 (optional), an internal probe is used to 
information items provides a more or less independent aid in navigation of the probe to a target site (e.g., using 
dimension in a “medical condition space” of dimension optical reflectance of organs and/or tissu%s along a path to 
Nl+N2+N3. Preferably, each r ~ ~ d i c a l  condition that is the target site), with appropriate confidence levels incorpo- 
Present in, Or is whob’ Or largely Consistent With, the 55 rated. In step 63, two or more internal measurements are 
measurements in each of these dimensions has an associated performed at the target site using the probe, with appropriate 
confidence level, with values ran!$’@ from 0 Percent to 100 confidence levels incorporated. In step 65 (optional), one or 
percent. more external measurements are performed at the target site, 
Presence of a medical condition, especially a non-normal with appropriate confidence levels incorporated. In step 67 
one, in each of two or more such dimensions ai3rmatively 60 (optional), one or more heuristic information items concem- 
indicates the possible presence of that medical condition, as ing the target site are included, with appropriate confidence 
discussed in the preceding. When this occurs, an initial levels incorporated. In step 69, a group of one or more 
diagnosis uses the set intersection of the medical conditions medical conditions, each of which is generally consistent 
in each dimension to provide a list of medical conditions that with the internal measurements, with the (optional) external 
is consistent with the medical conditions present in each 65 measurements, and with the (optional) heuristic information 
dimension. FIG. 3 graphically illustrates provision of a items, is provided. In some instances, an internal measure- 
reduced group of medical conditions from intersection of ment, an external measurement and/or a heuristic informa- 
eters for the patterns. Fuzzy logic is discussed by B. A ninth probe mechanism 17-9 measures local pH associated 
1993, pp. 78-81. 
Data from 
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tion item that is inconsistent with the remainder of the data 
for the target site may be either ignored or given much 
smaller weight, or even negative weight, in determining this 
group of medical conditions. In step 71, at least one medical 
condition from the provided group is identified as likely to 
be present for the test subject. 
One approach to processing and analyzing the results of 
comparison of one or more internal measurements at a target 
site with selected reference values corresponding to a nor- 
mal or benign medical condition, or corresponding to a 
malignant (tumorous) medical condition, is through neural 
net processing. At least two dternatives are available: radial 
basis neural net modeling and backpropagation modeling. 
Radial basis neural net modeling (“NNM”) is summarized 
in Neural Network Toolbox For Use With Matlab, The Math 
Works, Third Version, 1998, pp. 6-1 through 6-19, and is 
characterized in FIG. 7. This neural network includes three 
layers, an input layer 81, one or more hidden layers 83, and 
an output layer 85. The input layer 81 accepts an input vector 
p, forms a difference between the vector p and an input 
weight vector w, optionally multiplies the difference p-w by 
a selected bias or sensitivity vactor b to form a scalar 
product, and passes this scalar product to an intermediate 
layer for further processing and analysis. 
The dimension N of the vectors p and w may be the total 
number of independent internal measurements plus indepen- 
dent external measurements plus heuristic information items 
presented for the test subject. For example, if three internal 
measurement sets (1,3,7), one external measurement set (4) 
and one heuristic information item (1) are presented, as in 
FIG. 3, the dimension N= 3+1+1=5. More likely, the dimen- 
sion N will be a larger number, in order to obtain discrimi- 
nation between two medical conditions having similar data 
for “lower dimensional” measurements. 
The radial basis neural network (“RBNN”), shown sche- 
matically in FIG. 7 ,  will produce an output value OUT that 
is close to zero, if the vectors p and w differ substantially 
from each other and will produce an output value OUT=1 if 
the vectors p and w are (nearly) equal to each other. One 
object of processing by an RBNN is to identify an input 
vector p that provides an output value that is close to, or 
equal to, 1 for one or more of a selected sequence of input 
weight vectors w. In this RBNN analysis, more than one 
input weight vector w may be used at the same time. 
Consider an R-dimensional space S having a finite col- 
lection of Q reference data points therein, each with coor- 
dinates x(q)=(xql, xq2,. . . , xqR) (q=l, 2,. . . , Q), with each 
point in this collection representing a reference data point 
with an associated medical condition for a selected target 
site. The data represented by the point x(q) are taken from 
certified observations made on one or more reference test 
subjects and include data from internal measurements, from 
external measurements and from heuristic information on 
medical condition of the target site. Preferably, each R-di- 
mensional space S is associated with a different target site 
(brain, heart, liver, pancreas, kidney(s), intestines, lung(s). 
thorax, selected tissues, selected groups of cells associated 
with a given organ, etc.) for the reference test subjects. Each 
reference data point x is associated with one of K=2 medical 
conditions for the target site: malignant (M) or normal/ 
benign (B). More generally, each reference data point x is 
associated with one of K (22) selected medical conditions 
for the target site. 
Assume that a patient (a non-reference test subject) is 
subjected to probing with the probe and/or scanning accord- 
ing to the invention for a selected target site and that internal 
and/or external measurements produce at least one observed 
10 
data point y=(yl, y2, . . . , yR) in the space S .  The distances 
{d(x(q);y)} (q=l, 2, . . . , Q) are compared with each other, 
and at least one reference data point x(q0) satisfies 
dcx(4o),y)=min,Id(x(q);y)}. (1) 
5 
The distance d(x(q);y) may be defined generally as 
where w, is a selected non-negative weight value and s is a 
15 selected positive number. The choice {wr=l, s=2} recovers 
the conventional Euclidean distance metric. A more general 
distance metric d(x(q);y) may also be used here that satisfies 
three standard requirements for a metric: (1) d(x,y)20, (2) 
d(x,y)= d(y,x) and (3) d(x,z)+d(z,y)Wx,y). 
Assume, for definiteness, that a reference data point 
x(MI), belonging to the malignant set M, is found to be 
closest to the observed data point y so that x(qO)=x(Ml) 
satisfies the relation (1). For illustrative purposes, the two 
next-nearest reference data points are assumed to be x(B 1) 
25 and x(B2), belonging to the normalhenign set (referred to 
collectively as the “normal” set) B. For purposes of initial 
illustration, the dimension of the space S is assumed to be 
R=l in FIG. 8A so that the space is a line segment, having 
a single coordinate y, with each reference data point having 
Observed data points y that are “close to” a reference data 
point, such as x(M1), on this line segment will have a 
correspondingly high overall probability Pr[y] that the medi- 
cal condition of the target site belongs to the malignant set 
35 M. Observed data poiints on this line segment that are “close 
to” a reference data point, such as x(B1) or x(B2), on this 
line segment will have a correspondingly high overall prob- 
ability that the medical condition of the target site belongs 
to the normal set B. A probability function 
20 
30 a location on that line segment. 
40 Pr(xfq);y)=F(d(x(q);y),q) (3) 
is assigned to each of the Q reference data points, where F 
is a monotonically decreasing (preferably continuous) func- 
tion of the distance d(x(q);y) between the observed data 
45 point y and the reference data point x(q). Each function F 
satisfies OSFS 1 and may vary with the index q as well. In 
one version of the first and second embodiments, the prob- 
ability function F(d(x(q);y);q) is the same for all reference 
data points x(q) belonging to a malignent medical condition 
50 set (M) and is the same for all reference data points x(q) 
belonging to a normal medical condition set (B). Use of a 
probability function F that varies more generally with the 
index q complicates the analysis but can ke incorporated. 
Suitable classes of probability functions F include exponen- 
F(d(x;y))=expI-a.d(x;y)p}, (4.4) 
55 tial 
inverse polynomial 
60 F(d(x;y))=nl{P+Xd(x;y)‘}, (4B) 
and linear or nonlinear 
F(d(x;y))=a-P.Id(x;y~}, (4C) 
65 where a, p, x and p are selected real numbers. 
If the reference data point x(q) corresponds to a malignant 
medical condition (or to a normal medical condition), F(d 
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(x(q);y);q) corresponds to a probability that the observed 
data point is indicative that the observed data point belongs 
to the set M (or to the set B). FIG. 8B graphically illustrates, 
in one dimension, three typical probability functions for the 
reference data points B1, M1 and B2. Note that, for example, 
the probability functions corresponding to B1, to B2 and to 
M1 need not be the same. The one-dimensional situations 
illustrated in FIGS. 8A and 8B are easily generalized to R 
dimensions, using the distance metric d(x(q);y). The relative 
positions of the data points B1, B2 and M1 may be changed 
as long as at least one normal data point (B1 or B2) and at 
least one malignant data point (Ml) are present. 
In one embodiment, the overall probability associated 
with the target site (represented by the observed data point 
Pr [y l=~~(d (x (q ) ;y ) ;q ) ,  (5) 
and the corresponding medical condition for the target site 
is the medical condition for the reference data point@) x(q0) 
satisfying Eq. (l), denoted herein as MC(x(q0)). In the 
one-dimensional illustration in FIG. 8B, the overall prob- 
ability would be determined by 
Y) is 
where xsl,M1 is the value of y at which F(d(x(B1);y) and 
F(d(x(M1);y) are equal and x , , , ~ , ~ ~  is the value of y at which 
F(d(x(M1);y) and F(d(x(B2);y) are equal. 
If, for a given observed data point y, J reference data 
points x(q0j) (j=1, . . . , L) are found that satisfy Eq. (l), with 
J21, a modified overall probability Pr(y}/J is assigned to 
each of the medical conditions associated with the data 
points x(q0j). Where all J medical conditions are the same, 
that medical condition is assigned an overall probability of 
Pr[y] for the target site. Where two (or more) different 
medical conditions occur, denoted as MC(x(qOj1)) and 
MC(x(qOj2)) for definiteness, corresponding to different 
reference data points that each satisfy Eq. (l), a modified 
overall probability assigns a portion of the probability 
PR[y], defined in Eq. (5) to each of the medical conditions 
MC(x(q0j 1)) and MC(x(qOj2)). 
In a second embodiment, given the observed data point y, 
a first nearest-neighbor reference data point x(q0l) and a 
second nearest-neighbor reference data point x(q02), corre- 
sponding to a malignant medical condition and to a normal 
medical condition, respectively, are identified, with corre- 
sponding probability functions as defined in Eq. (3). The 
probability that the target site is malignant and the prob- 
ability that the target site is normal are then taken to be 
PrCV ~=F(d(x(sl);y);41)/(Sum) (7) 
and 
P r o  EB)=F(d(x(q2);y);q2)/(SUm), (8) 
respectively, with 
SUm=F(d(X(ql);y);ql )+F(d(X(qZ);y);q2) (9) 
The definitions (7), (8) and (9) ensure that the sum of the 
probabilities for the two independent events {y E M} and {y 
E B} is non-negative and is no greater than 1.0. The 
definitions (7), (8) and (9) extend to a situation where more 
than one reference data point x(q) E M satisfies Eq. (1) 
andor where more than one reference data point x(q) E B 
satisfies Eq. (1). 
Each of the first and second embodiments extends from 
5 dimension R=l to any higher integer dimension R. Other 
formulations of the overall probability Pr[y] associated with 
the observed data pointy can also be used here. This analysis 
can be combined with an RBNN approach to train a network 
and to assign probabilities to different medical conditions at 
10 a target site, based on comparison of observed and reference 
data points. 
Another useful neural net modeling technique is back- 
propagation, wherein NN input vectors and NN output 
vectors are analyzed and used to train a network to associate 
15 specific input vectors with specific output vectors and to 
associate NN input vectors in a desired manner. Standard 
backpropagation uses a gradient descent analysis, using a 
conjugate gradient, Newton or other suitable approach. The 
backpropagation method is summarized in Neural Network 
20 Toolbox For Use With Matlab, The Math Works, Third 
Version, 1998, pp. 5-1 through 5-56. 
FIG. 8 indicates schematically what an RBNN seeks to 
accomplish. A first sequence of input vectors or points p(i) 
in N-dimensional space is provided (N=2 in the represen- 
25 tation of FIG. 8), a second sequence of input weight vectors 
or points u(i) is also provided, and differences Au(i,j)=u(i) 
-u(j) are formed. One object of a, linear RBNN is to identify 
one or more input vectors that minimize the perpendicular 
distances d(p,Au(ij)) between the vector p and the vectors 
30 Au(ij), as illustrated in FIG. 8. It is unlikely that a single 
input vector p can be found that minimizes all the distances 
d(p,Au(i,j)), but one or more vectors p may be identifiable 
for which the weighted sum 
4o is minimized, where b(ij) is a non-negative weight assigned 
to the pair of input weight vectors w(i) and w(j). For 
normalization purposes, one may restrict the input vectors p 
to a specified subset, such as the set of all vectors p with unit 
length: l/pll=l. The relation 
E(q)=maximum (2) 
among all vectors q with unit length has a well defined 
mathematical solution, but he set of available input vectors 
p may not include the exact solution vector q for Eq. (2). 
50 Thus, one may have to search among the available input 
vectors for one or more vectors p that comes closest to 
satisfying Eq. (2). An RBNN is one method for identifying 
this optimum vector p. Once an optimum vector p is 
identified, one can determine confidence levels associated 
55 with the optimum vector p belonging to a first medical 
condition set (e.g., cancer at the target site) and with the 
optimum vector p belonging to a second medical condition 
set (e.g.. a benign or normal condition at the target site). 
45 
60 What is claimed is: 
1. A system for estimating a medical condition associated 
with a target site in an animal body, the system comprising: 
a first database that contains R-dimensional vector values 
x(q) of reference values of measurements that charac- 
terize one or more medical conditions of the target site 
in the animal body, with q in Q1 or q in Q2, where Q1 
and Q2 are mutually exclusive index sets, where each 
65 
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vector value x(q) in the first database is associated with =exp{-azp}, F(z)={P+Xz'}9and F(z)=p-vd, where a, P, 
a first set SI of medical conditions, corresponding to q x, y, p, v, p, r and s are selected non-negative values. 
being a member of QI, or with a second set 52 of 6. The system of claim 4, wherein said metric d(x(q);y;q) 
medical conditions, corresponding to q being a member depends upon said vectors x(q) and y and depends upon said 
of Q2, where S1 and S2 are mutually exclusive and R 5 index q only through said vector x(q). 
is a selected positive integer; 7. The system of claim 4, wherein, for at least two distinct 
a second database that contains vector values y in a set S3 values q' and q" with corresponding vectors x(q') in said set 
of one or more measurements made at or adjacent to the SI and x(q") in said set S2, said metric value d(x(q');y;q') 
target site, where y is a P-dimensional vector and P is differs from said metric value d(x(q");y;q") for at least one 
a selected positive integer with PSR; and 
a computer that is programmed to form a non-negative, 8. The system of claim 4, wherein each of said functions 
real-valued medical condition function of a metric F(d(x(q);y;q)) is chosen to satisfy O5max, tn s3 F(d(x(q);y; 
distance between the vector x(q) and one or more of the 9)) 1 for each vector x(q) and said computer is further 
vector values y. where the medical condition function pmgrammed to interpret said value F(d(x'(q);y;q)) for at 
distinguishes between a first medical condition in 15 least one vector x'(q) in said set S1 as a probability that said 
which y is more likely associated with the first set S 1 measurement vector y belongs to said set S 1.  
and a second medical condition in which y is more 9. The system of claim 4, wherein each of said functions 
likely associated with the second set S2. F(d(x(q);y;q)) is chosen to satisfy OSmax, in ,F(d(x(q);y; 
2. The system of claim 1, wherein at least one of said sets q))S 1 for each vector x(q) and said computer is further 
S1 and S2 corresponds to at least one of a normal medical 20 Programed to interpret said value F(d(x'(q);Y;q)) for at 
condition and a benign medical condition. least one vector x'(q) in said set S2 as a probability that said 
memurement vector Y belongs to Said Set s2. 
S1 and S2 corresponds to a malignant medical condition. 10. The system of claim 4, wherein at least one of said sets 
and S2 corresponds to at least one of a normal medical 
with a target 
11. The system of claim 4, wherein said at least one of said 
and s2 corresponds to a malignant medical condi- 
12. A method for estimating a medical condition associ- 
10 measurement vector y. 
3. The system of claim 1, wherein at least one of said sets 
4. A system for estimating a medical condition associated 
a first database that contains R-dimensional vector values 
x(q) of reference values of measurements that charac- 
terize one or more medical conditions of the target site 
in the animal body, with in ~1 or in 42, where ~1 
vector value x(q) in the first database is associated with 
a first set ~1 of 
being a member of Q1, or with a second set S2 of 
medical conditions, corresponding to q being a member 
of 42, where SI and S2 are mutually exclusive and R 35 
is a selected positive integer; 
a second database that contains vector values y in a set 53 
of one or more measurements made at or adjacent to the 
target site, where y is a P-dimensional vector and P is 
a selected positive integer with PSR; and 
to form a non-negative, real-valued metric d(x(q);y;q), 
depending upon vectors x(q) and y drawn from the 
index q; 
in an animal body, the system comprising: 25 condition and a benign medical condition. 
Sets 
tion. 
and 4 2  are mutually exclusive index sets, where each 30 ated With a target Site in an animal body, the method 
comprising: 
conditions, corresponding to providing a first database that contains R-dimensional 
vector values x(q) of reference values of measurements 
that characterize one or more medical conditions of the 
target Site in the animal body, with q in Q1 or q in 42, 
where Q1 and Q2 are mutually exclusive index sets, 
where each vector value x(q) in the first database is 
associated with a first set SI of medical conditions, 
corresponding to q being a member of Q1, or with a 
second set S2 of medical conditions, corresponding to 
q being a member of 42, where S1 and S2 are mutually 
exclusive and R is a selected positive integer; 
providing a second database that contains vector values y 
in a set S3 of one or more measurements made at or 
vector and P is a selected positive integer with PSR; 
and 
form a non-negative, real-valued medical condition 
function of a metric distance between the vector x(q) 
and one or more of the vector values y, where the 
medical condition function distinguishes between a 
first medical condition in which y is more likely in the 
first set S1 and a second medical condition in which y 
is more likely in the second set s2. 
13. The method of claim 12, further comprising choosing 
said at least one of said sets S 1 and S2 to correspond to at 
least one of a normal medical condition and a benign 
medical condition. 
14. The method of claim 12, further comprising choosing 
at least one of said sets s1 and S2 to correspond to a 
malignant medied condition. 
15. A method for estimating a medical condition associ- 
ated with a target site in an animal body, the method 
providing a first database that contains R-dimensional 
vector values x(q) of reference values of measurements 
40 
a computer that is programmed: 
first and second databases, and the 45 adjacent to the target site, where is a p-dimensional 
to form a medical condition function F(d(x(q);y;q)), 
F is a selected non-negative, monotonically decreas- 
ing function of the metric value d(x(q);y;q); 
to compute the quantities Fl(y)=max,,,cq, s,F(d(w(q); 
Y ;q)) and F~(YI=~-(,) tn .&Td(w(q);y;q)); 
when Fl(y)>F2(y), to interpret the value Fl(y)/{Fl(y) 
+F2(y)} as a lower bound on a probability that the 
IneaSUrement Value y is associated with the first Set 55 
SI, and to interpret the value F2(y)l{F1 (y)+F2(Y)} 
as an Upper bound On a Probability that the measure- 
ment value Y is associated with the first set s2; and 
when Fl(y)&2(y), to interpret the value Fl(y)/{Fl(y) 
+F~(Y)} as an upper bound on a probability that the 60 
measurement value y is associated with the first set 
SI, and to interpret the value F~(Y)/{F~(Y)+F~(Y)} as 
a lower bound on a probability that the measurement 
value y is associated with the first set S2. 
depending the metric values d(x(q);y;q), where programming providing a computer that is programmed to 
50 
5. The system of claim 4, wherein said computer is further 65 comprising: 
programmed to draw said function F(z) for a non-negative 
value z from a group of functions consisting of F(z) 
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that characterize one or more medical conditions of the 
target site in the animal body, with q in Q1 or q in Q2, 
where Q1 and Q2 are mutually exclusive index sets, 
where each vector value x(q) in the first database is 
associated with a first set SI of medical conditions, 
corresponding to q being a member of Q1, or with a 
second set S2 of medical conditions, corresponding to 
q being a member of Q2, where S1 and S2 are mutually 
exclusive and R is a selected positive integer; 
providing a second database that contains vector values y 
in a set S3 of one or more measurements made at or 
adjacent to the target site, where y is a P-dimensional 
vector and P is a selected positive integer with P S R  
and 
to form a non-negative, real-valued metric d(x(q);y;q), 
depending upon vectors x(q) and y drawn from the 
first and second databases, respectively, and upon the 
index q; 
to form a medical condition function F(d(x(q);y;q)), 
depending upon the metric values d(x(q);y;q), where 
F is a selected non-negative, monotonically decreas- 
ing function of the metric value d(x(q);y;q); 
to compute the quantities Fl(y)=max,,,,,, .,F(d(w(q); 
when Fl(y)>F2(y), to interpret the value Fl(y)/{Fl(y) 
+F2(y)} as a lower bound on a probability that the 
measurement value y is associated with the first set 
S1, and to interpret the value F2(y)/{Fl(y)+F2(y)} as 
an upper bound on a probability that the measure- 
ment value y is associated with the first set S2; and 
when Fl(y)<F2(y), to interpret the value Fl(y)/{Fl(y) 
+F2(y)} as an upper bound on a probability that the 
measurement value y is associated with the first set 
S 1, and to interpret the value F2(y)/(FI (y)+F2(y)} as 
a lower bound on a probability that the measurement 
value y is associated with the first set S2. 
16. The method of claim 15, further comprising program- 
ming said computer to draw said function F(z) for z 2 0  from 
providing a computer that is programmed: 
y;q)) and F2(y)=max,,,(,, ,,F(d(w(q);y;q)); 
16 
a group of functions consisting of F(z)=exp{-af}, F(z) 
={P+Xd)"' and F(z)=p-vd, where a, b, x, y, p, v, p, r and 
s are selected non-negative values. 
17. The method of claim 15, further comprising program- 
ming said metric d(x(q);y;q) to depend upon said vectors 
x(q) and y and depends upon said index q only through said 
vector x(q). 
18. The method of claim 15, wherein, for at least two 
distinct values q' and q", with corresponding vectors x(q') in 
said set S1 and x(q") in said set S2, further comprising 
programming said metric value d(x(q');y;q') to differ from 
said metric value d(x(q");y;q") for at least one measurement 
vector y. 
19. The method of claim 15, further comprising program- 
ming each of said functions F(d(x(q);y;q)) to satisfy OSmaxy 
nF(d(x(q);y;q))S 1 for each vector x(q) and further com- 
l5 
prising programming said computer to interpret said value 
F(d(x'(q);y;q)) for at least one vector x'(q) in said set SI as 
a probability that said measurement vector y belongs to said 
set SI. 
20 
20. The method of claim 15, further comprising program- 
ming each of said functions F(d(x(q);y;q)) to satisfy OSmaxy 
nF(d(x(q);y;q))S 1 for each vector x(q) and further com- 
prising programming said computer to interpret said value 
F(d(x'(q);y;q)) for at least one vector x'(q) in said set S2 as 
a probability that said measurement vector y belongs to said 
set S2. 
21. The method of claim 15, further comprising program- 
ming said computer so that at least one of said sets SI and 
S2 corresponds to at least one of a normal medical condition 
and a benign medical condition. 
22. The method of claim 15, further Comprising program- 
ming said computer so that at least one of said sets S1 and 
S2 corresponds to a malignant medical condition. 
25 
30 
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